| Literature DB >> 26425417 |
Ying Huang1, Jing Ma2, Alan L Porter3, Seokbeom Kwon4, Donghua Zhu2.
Abstract
The rapid development of new and emerging science & technologies (NESTs) brings unprecedented challenges, but also opportunities. In this paper, we use bibliometric and social network analyses, at country, institution, and individual levels, to explore the patterns of scientific networking for a key nano area - nano-enabled drug delivery (NEDD). NEDD has successfully been used clinically to modulate drug release and to target particular diseased tissues. The data for this research come from a global compilation of research publication information on NEDD directed at brain cancer. We derive a family of indicators that address multiple facets of research collaboration and knowledge transfer patterns. Results show that: (1) international cooperation is increasing, but networking characteristics change over time; (2) highly productive institutions also lead in influence, as measured by citation to their work, with American institutes leading; (3) research collaboration is dominated by local relationships, with interesting information available from authorship patterns that go well beyond journal impact factors. Results offer useful technical intelligence to help researchers identify potential collaborators and to help inform R&D management and science & innovation policy for such nanotechnologies.Entities:
Keywords: bibliometrics; brain cancer; collaboration network; nano-enabled drug delivery (NEDD); nanoinformatics
Year: 2015 PMID: 26425417 PMCID: PMC4578350 DOI: 10.3762/bjnano.6.169
Source DB: PubMed Journal: Beilstein J Nanotechnol ISSN: 2190-4286 Impact factor: 3.649
Search Strategy of NEDD for Brain Cancer in Web of Science.
| Set | Category | Records | Search Terms |
| # 1 | T (Target) | 63,707 | TS = (((brain or "central nervous system" or CNS) near/1 (cancer* or anticancer* or tumor* or tumour* or oncology or neoplasm* or carcinoma*)) or glioma* or glioblastoma*) |
| # 2 | N (nanoparticles and materials) | 1,135,180 | TS = (nano* or micelle* or liposome* or dendrimer* or metal complex* or hydrogel* or “quantum dots*” or chitosan* or alginate*) |
| # 3 | M (Medicine) | 128,626 | TS = (temozolomide or procarbazine or carmustine or BCNU or lomustine or CCNU or vincristine or everolimus or irinotecan or cisplatin or carboplatin or methotrexate or etoposide or bleomycin or vinblastine or actinomycin or dactinomycin or cyclophosphamide or ifosfamide) |
| # 4 | P (Pharmaceutical) | 40,937 | TS = (siRNA or "short interfering RNA" or "small interfering RNA") |
| # 5 | D (delivery systems) | 4,936,370 | TS = (deliver* or vehicle* or carrier* or vector* or treat* or therap* or "control* releas*" or "sustain* releas*" or transduct* or transfect* or transport* or translocat*) |
| # 6 | Final | 1859 | #1 AND #2 AND (#3 OR #4 OR #5) |
Figure 1NEDD for brain cancer research across the disciplines.
Figure 2Publication trend of top 10 countries in 1990–2014.
Centrality analysis for top 10 countries in different stages.
| 1990–1999 | 2000–2009 | 2010–2014 | |||||||
| DC | CC | BC | DC | CC | BC | DC | CC | BC | |
| USA | 8 | 0.833 | 0.208 | 23 | 0.706 | 0.340 | 35 | 0.709 | 0.392 |
| China | 0 | 0.000 | 0.000 | 6 | 0.486 | 0.011 | 11 | 0.519 | 0.030 |
| Japan | 1 | 0.476 | 0.000 | 7 | 0.522 | 0.044 | 11 | 0.514 | 0.057 |
| Germany | 3 | 0.588 | 0.084 | 16 | 0.643 | 0.225 | 21 | 0.596 | 0.099 |
| France | 2 | 0.500 | 0.000 | 7 | 0.522 | 0.054 | 19 | 0.554 | 0.115 |
| Italy | 0 | 0.000 | 0.000 | 5 | 0.468 | 0.006 | 18 | 0.583 | 0.091 |
| India | 0 | 0.000 | 0.000 | 3 | 0.439 | 0.001 | 11 | 0.500 | 0.017 |
| South Korea | 0 | 0.000 | 0.000 | 1 | 0.419 | 0.000 | 10 | 0.519 | 0.015 |
| Canada | 3 | 0.526 | 0.003 | 5 | 0.500 | 0.003 | 12 | 0.533 | 0.058 |
| UK | 1 | 0.476 | 0.000 | 13 | 0.581 | 0.139 | 11 | 0.519 | 0.021 |
Figure 3Scatter plot of international collaboration index (ICI) for top 10 countries in (a) 1990–1999; (b) 2000–2009; (c) 2010–2014. The guides indicate the average value of these top 10 countries.
Figure 4Publications of the top 12 institutions in 1990–2014.
Publications and citation information for the top 12 institutions.a
| Organization | Records | Average times cited | Median times cited | Average times citing | Country |
| Fudan Univ | 95 | 19.9 | 12.0 | 13.0 | China |
| Nagoya Univ | 53 | 25.5 | 14.0 | 17.0 | Japan |
| Univ Michigan | 51 | 52.9 | 27.0 | 38.3 | USA |
| Ohio State Univ | 40 | 35.5 | 27.0 | 24.0 | USA |
| Harvard Univ | 37 | 52.0 | 19.5 | 46.4 | USA |
| Univ Calif San Francisco | 35 | 38.7 | 32.0 | 23.9 | USA |
| Johns Hopkins Univ | 31 | 24.6 | 10.0 | 23.1 | USA |
| Tianjin Univ | 28 | 32.0 | 14.0 | 26.6 | China |
| Univ Washington | 27 | 47.3 | 21.0 | 35.5 | USA |
| INSERM | 24 | 13.8 | 7.5 | 11.8 | France |
| Natl Univ Singapore | 24 | 63.2 | 26.5 | 57.4 | Singapore |
| Shanghai Jiao Tong Univ | 24 | 13.2 | 3.0 | 10.7 | China |
aCitation counts include self-citation.
Figure 5Collaboration activity of the top 12 institutions.
Figure 6Co-author network of the top 20 authors.
Top 20 authors in NEDD for brain cancer.
| Authors | Records | 1st-Author records | Average citations | h-index | Organization | Country | Research area |
| Yoshida, Jun | 46 | 7 | 24.59 | 18 | Nagoya Univ | Japan | Oncology; |
| Mizuno, M | 39 | 8 | 18.74 | 15 | Nagoya Univ | Japan | Oncology; |
| Jiang, Xinguo | 36 | 0 | 21.36 | 14 | Fudan Univ | China | Materials Science; |
| Benoit, Jean-Pierre | 35 | 0 | 16.4 | 13 | Univ Angers | France | Pharmacology & Pharmacy; Chemistry |
| Kopelman, Raoul | 31 | 1 | 61.97 | 19 | Univ Michigan | USA | Chemistry; |
| Pang, Zhiqing | 27 | 2 | 22.71 | 14 | Fudan Univ | China | Materials Science; |
| Gao, Huile | 25 | 14 | 12.81 | 9 | Fudan Univ | China | Pharmacology & Pharmacy; |
| Kreuter, Joerg | 23 | 3 | 68.26 | 18 | Univ Frankfurt | Germany | Pharmacology & Pharmacy; Chemistry |
| Barth, Rolf F | 21 | 3 | 51.9 | 17 | Ohio State Univ | USA | Oncology; |
| Passirani, Catherine | 20 | 0 | 15.5 | 10 | Univ Angers | France | Pharmacology & Pharmacy; |
| Zhang, Miqin | 19 | 0 | 53.68 | 13 | Univ Washington | USA | Materials Science; |
| Bankiewicz, Krystof S | 18 | 0 | 38.35 | 13 | Univ Calif San Francisco | USA | Neurosciences & Neurology; Oncology |
| Park, John W | 17 | 1 | 53.83 | 14 | Univ Calif San Francisco | USA | Neurosciences & Neurology; Oncology |
| Wakabayashi, Toshihiko | 17 | 2 | 32.24 | 11 | Nagoya Univ | Japan | Oncology; Research & Experimental Medicine |
| Chen, Jun | 16 | 0 | 18.48 | 11 | Fudan Univ | China | Materials Science; Enginerring |
| Garcion, Emmanuel | 16 | 1 | 19.56 | 9 | Univ Angers | France | Pharmacology & Pharmacy; |
| Philbert, Martin A | 16 | 0 | 86.25 | 15 | Univ Michigan | USA | Chemistry; |
| Saito, Ryuta | 16 | 7 | 47.81 | 11 | Univ Calif San Francisco | USA | Neurosciences & Neurology; |
| Yang, Victor C | 15 | 0 | 48.73 | 12 | Univ Michigan | USA | Materials Science; |
| Yang, Weilian | 15 | 6 | 13.6 | 8 | Ohio State Univ | USA | Oncology; |
Figure 7The author activities of top 20 authors in NEDD for brain cancer.